Bank of America’s Innate Pharma IPHA Stock Holding History

Bank of America’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-46,749	Closed	-$133K	–	7820
2023 Q1	$133K	Sell	46,749 -109,042	-70%	-$350K	﹤0.01%	6131
2022 Q4	$581K	Sell	155,791 -8,987	-5%	-$20.5K	﹤0.01%	5270
2022 Q3	$330K	Sell	164,778 -10,451	-6%	-$28.2K	﹤0.01%	5681
2022 Q2	$473K	Buy	175,229 +45	+0%	+$131	﹤0.01%	5472
2022 Q1	$589K	Sell	175,184 -71,867	-29%	-$265K	﹤0.01%	5714
2021 Q4	$1.13M	Buy	247,051 +72,951	+42%	+$388K	﹤0.01%	5123
2021 Q3	$1.07M	Buy	+174,100	New	+$750K	﹤0.01%	4994

Other funds holding IPHA

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's IPHA Position: Q2 2023 in Review

Bank of America sold out of Innate Pharma (IPHA) in Q2 2023, closing a stake of 46,749 shares — an estimated $133K sold.

Bank of America first reported a position in IPHA in Q3 2021 and held it in 7 quarters. The position peaked at $1.13M in Q4 2021. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2023.

Bank of America reported no remaining Innate Pharma position as of Q2 2023 after selling out during the quarter.
Bank of America sold 46,749 Innate Pharma shares in Q2 2023, an estimated $133K.
Bank of America first reported a position in Innate Pharma in Q3 2021 and held it in 7 quarters.
Bank of America's Innate Pharma position peaked at $1.13M in Q4 2021.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2023.

Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.